| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CAREMAX Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 249,75 | +0,40 % | UnitedHealth-Aktie: Schockmeldung - droht der komplette Absturz? | ||
| INTUITIVE SURGICAL | 430,25 | +0,53 % | Intuitive Surgical: Steht ein weiterer Rücksetzer bevor? | Die Intuitive-Surgical-Aktie zeigt seit dem Jahreswechsel eine deutlich schwächere Struktur. Rutscht der Kurs in Richtung der nächsten Unterstützung ab Den vollständigen Artikel lesen ... ► Artikel lesen | |
| THERMO FISHER | 447,10 | 0,00 % | Thermo Fisher Prices $3.8 Bln Senior Notes To Fund Clario Acquisition | WASHINGTON (dpa-AFX) - Thermo Fisher Scientific Inc. (TMO), a life science and clinical research company, on Tuesday announced it has priced a $3.8 billion senior notes offering to partially... ► Artikel lesen | |
| ROKU | 83,96 | -0,69 % | Cathie Wood's ARK sells Roku stock, buys Robinhood and DraftKings | ||
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | XFRA 7300,B0Y,YAG: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILZEROSTACK CORP.... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| CENTENE | 37,670 | +0,99 % | Centene Guides FY26 Adj. EPS Above Estimates As Q4 Results Top Estimates | WASHINGTON (dpa-AFX) - While reporting financial results for the fourth quarter on Friday, healthcare company Centene Corp. (CNC) initiated its earnings, adjusted earnings and total revenue... ► Artikel lesen | |
| QUIDELORTHO | 18,400 | -0,54 % | QuidelOrtho präsentiert Wachstumsstrategie auf Raymond James Konferenz | ||
| VERU | 2,550 | +0,39 % | Veru Inc.: Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress | -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter- --Company to host conference call and webcast... ► Artikel lesen | |
| NANO-X IMAGING | 2,590 | 0,00 % | Nanox signs distribution deal for imaging system in Southeast U.S. | ||
| TEMPEST THERAPEUTICS | 1,940 | -100,00 % | Tempest Therapeutics: Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 | 100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade - 3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression... ► Artikel lesen | |
| FULGENT GENETICS | 12,400 | +0,81 % | Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix | ||
| LANTHEUS | 65,84 | +0,12 % | Lantheus receives FDA tentative approval for generic cancer drug | ||
| PERSPECTIVE THERAPEUTICS | 4,560 | +3,64 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results | SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 19,300 | 0,00 % | AMN Healthcare Services Inc: AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results | Quarterly revenue of $748 million- GAAP loss of ($0.20)/share and adjusted EPS of $0.22DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator... ► Artikel lesen |